1. Disability-adjusted life years (DALYs). Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/158. Accessed 23 Aug 2024
2. Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E et al (2020) The burden of neurological diseases in Europe: an analysis for the global burden of disease study 2017. Lancet Public Heal 5(10):e551–e567
3. Reoma LB, Karp BI (2022) The human cost: patient contribution to clinical trials in neurology. Neurotherapeutics 19(5):1503–1506
4. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized phase 3 studies of aducanumab in early alzheimer’s disease. J Prev Alzheimer’s Dis 9(2):197–210
5. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early alzheimer’s disease. N Engl J Med [Online] 388(1):142–143